Celltrion, “We’re preparing for the U.S. FDA’s onsite inspection for our first global generic”

In response to the Korea Exchange’s request of inquiry notice on the 17^th, Celltrion officially announced on the 18^th “We carefully reviewed each item on Paragraph 1 of Article 6 of the KOSDAQ’s Posting Regulations and its impacts to stock price and exchange volume, and we have no important information to officially notice in regards to recent changes in the market condition(sudden increase of ...